Targeting Doxorubicin to Ovarian Cancer with Immunoliposomes
Author Information
Author(s): MH Vingerhoeds, PA Steerenberg, JJGW Hendriks, LC Dekker, QGCM van Hoesel, DJA Crommelin, G Storm
Primary Institution: Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University
Hypothesis
Does immunoliposome-mediated targeting of doxorubicin enhance its anti-tumor effect compared to non-targeted liposomes?
Conclusion
The study found that while immunoliposomes showed superior binding to ovarian cancer cells in vitro, there was no significant difference in anti-tumor effects compared to non-targeted liposomes in vivo due to premature drug leakage.
Supporting Evidence
- Immunoliposomes showed superior binding to ovarian cancer cells in vitro.
- Both immunoliposomes and non-targeted liposomes induced significant tumor growth inhibition in vivo.
- Premature drug leakage from liposomes was identified as a key issue affecting anti-tumor efficacy.
Takeaway
Researchers tried to deliver a cancer drug better by using special bubbles called immunoliposomes, but they found out that the drug leaked out too soon, making it not work better than regular bubbles.
Methodology
The study involved in vitro and in vivo experiments using a xenograft model of ovarian carcinoma to assess the binding and anti-tumor activity of doxorubicin encapsulated in immunoliposomes versus non-targeted liposomes.
Limitations
The study did not observe significant differences in anti-tumor activity between targeted and non-targeted liposomes in vivo, likely due to drug leakage.
Participant Demographics
Nude mice bearing OVCAR-3 tumors were used for in vivo studies.
Statistical Information
P-Value
6x10^-5
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website